Skip to content

Neuropharmacology

ISSN 1873-7064

241 papers in the library · 4,645 citations · publishing 1982-2026

Papers

Sort Most recent Most cited

Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA).

Neuropharmacology June 2019 Daniel W Curry, Laís F. Berro, Andie R Belkoff et al.

The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well documented prosocial effects and is currently under clinical investigation as a treatment for patients with PTSD, autism, and other conditions. Early clinical trials have found that MDMA-assisted therapy may have robust long-lasting therapeutic effects, yet the mechanism by which acute treatments produce these long-term...

DOI: 10.1016/j.neuropharm.2019.03.017 (opens in new tab) Full text (opens in new tab) MDMA 3,4-methylenedioxymethamphetamine 5-ht2a Sensitization +1

Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.

Neuropharmacology 2019 Adam L. Halberstadt, Muhammad Chatha, Alexander Stratford et al. 25 citations

In recent years, rigid analogs of phenylalkylamine hallucinogens have appeared as recreational drugs. Examples include 2-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)ethan-1-amine (2C-B-FLY) and 1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane (Bromo-DragonFLY, DOB-DFLY). Although some rigid compounds such as DOB-DFLY reportedly have higher potency than their non-rigid...

The novel psychoactive substance methoxetamine induces persistent behavioral abnormalities and neurotoxicity in rats

Neuropharmacology 2019 Giulia Costa, Marcello Serra, Nicholas Pintori et al.

&NA; Methoxetamine (MXE) is a novel psychoactive substance that can induce several short‐term effects on emotional states and behavior. However, little is known about the persistent emotional and behavioral effects of MXE. Moreover, neurotoxic effects of MXE have been hypothesized, but never demonstrated in vivo. To clarify these issues, rats received repeated treatment with MXE every other day...

Concomitant THC and stress adolescent exposure induces impaired fear extinction and related neurobiological changes in adulthood.

Neuropharmacology January 2019 Rocio Saravia, Marc Ten-Blanco, Marina Julià-Hernández et al.

Δ9-tetrahydrocannabinol (THC) consumption during adolescence is reported to be a risk factor for the appearance of psychiatric disorders later in life. The interaction between genetic or environmental events and cannabinoid exposure in the adolescent period can also contribute to exacerbate behavioural deficits in adulthood. Here we investigate the effects of THC treatment as well as the...

DOI: 10.1016/j.neuropharm.2018.11.016 (opens in new tab) Full text (opens in new tab) Adolescence Amygdala Dendritic spines Fear extinction +2

Effects of acute Δ9-tetrahydrocannabinol on next-day extinction recall is mediated by post-extinction resting-state brain dynamics.

Neuropharmacology December 2018 Christine A Rabinak, Craig A Peters, Hilary A Marusak et al.

We have previously demonstrated that an acute dose of Δ9-tetrahydrocanninbinol (THC), administered prior to extinction learning, facilitates later recall of extinction learning and modulates the underlying neural circuitry, including the ventromedial prefrontal cortex (vmPFC), hippocampus (HPC), and amygdala (AMYG). It remains unknown whether THC-induced changes in fear-extinction neural...

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Neuropharmacology November 1, 2018 Elias Dakwar, Edward V. Nunes, Carl L. Hart et al. 83 citations

Efforts to translate sub-anesthetic ketamine infusions into widespread clinical use have centered around developing medications with comparable neurobiological activity, but with attenuated psychoactive effects so as to minimize the risk of behavioral toxicity and abuse liability. Converging lines of research, however, suggest that some of the psychoactive effects of sub-anesthetic ketamine may...

Positive psychology in the investigation of psychedelics and entactogens: A critical review

Neuropharmacology November 1, 2018 Henrik Jungaberle, Sascha Thal, Andrea Zeuch et al. 70 citations

RationaleWe reviewed the concepts and empirical findings in studies with psychedelics and entactogens related to positive psychology - the study of healthy human functioning, well-being and eudaemonia. It is an unresolved question how beneficial effects of psychedelics and entactogens are related to the potential risks of these substances - particularly in non-clinical settings.MethodsWe...

Why MDMA therapy for alcohol use disorder? And why now?

Neuropharmacology November 1, 2018 Ben Sessa 61 citations

Alcohol use disorder represents a serious clinical, social and personal burden on its sufferers and a significant financial strain on society. Current treatments, both psychological and pharmacological are poor, with high rates of relapse after medical detoxification and dedicated treatment programs. The earliest historical roots of psychedelic drug-assisted psychotherapy in the 1950s were...

Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Neuropharmacology November 1, 2018 Joshua S. Elmore, Ann M Decker, Agnieszka Sulima et al. 59 citations

2,5-Dimethoxyphenethylamines (2C compounds) are 5-HT2A/2C receptor agonists that induce hallucinogenic effects. N-methoxybenzylation of 2C compounds markedly increases their affinity for 5-HT2A receptors, and two such analogs, 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe),...

DOI: 10.1016/j.neuropharm.2018.02.033 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor Back muscle contractions Wet dog shakes Nbome compounds nbome +8

The serotonin hallucinogen 5-MeO-DMT alters cortico-thalamic activity in freely moving mice: Regionally-selective involvement of 5-HT1A and 5-HT2A receptors.

Neuropharmacology November 1, 2018 Maurizio S Riga, Laia Lladó-Pelfort, Francesc Artigas et al. 57 citations

5-MeO-DMT is a natural hallucinogen acting as serotonin 5-HT1A/5-HT2A receptor agonist. Its ability to evoke hallucinations could be used to study the neurobiology of psychotic symptoms and to identify new treatment targets. Moreover, recent studies revealed the therapeutic potential of serotonin hallucinogens in treating mood and anxiety disorders. Our previous results in anesthetized animals...

Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs.

Neuropharmacology November 1, 2018 Landon M. Klein, Nicholas V. Cozzi, Paul F. Daley et al. 43 citations

Substantial effort has been devoted toward understanding the psychopharmacological effects of tryptamine hallucinogens, which are thought to be mediated by activation of 5-HT2A and 5-HT1A receptors. Recently, several psychoactive tryptamines based on the N,N-diallyltryptamine (DALT) scaffold have been encountered as recreational drugs. Despite the apparent widespread use of DALT derivatives in...

DOI: 10.1016/j.neuropharm.2018.02.028 (opens in new tab) Full text (opens in new tab) 4-aco-dalt 4-Acetoxy-N,N-Diallyltryptamine 4-Hydroxy-N,N-Diallyltryptamine 5-MEO-Dalt +8

Ketamine for the treatment of addiction: Evidence and potential mechanisms.

Neuropharmacology November 2018 I Ivan Ezquerra-Romano, W Lawn, E Krupitsky et al.

Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid-acting anti-depressant but other studies have also reported its efficacy in reducing problematic alcohol and drug use. This review explores the preclinical and clinical research into...

Studies with psychedelic drugs in human volunteers.

Neuropharmacology November 2018 Edward M. Sellers, Myroslava K. Romach, Deborah B. Leiderman

Scientific curiosity and fascination have played a key role in human research with psychedelics along with the hope that perceptual alterations and heightened insight could benefit well-being and play a role in the treatment of various neuropsychiatric disorders. These motivations need to be tempered by a realistic assessment of the hurdles to be cleared for therapeutic use. Development of a...

A regulatory perspective on the evaluation of hallucinogen drugs for human use.

Neuropharmacology November 2018 Silvia N. Calderon, Joshua Hunt, Michael Klein

In recent years, there is renewed interest in the study of various hallucinogens for their potential therapeutic effects. In the United States of America (USA), the abuse potential assessment of a drug is carried out as part of the general safety and efficacy evaluation of a drug. Additionally, the abuse potential assessment is taken under consideration in determining if a drug needs to be...

DOI: 10.1016/j.neuropharm.2017.11.028 (opens in new tab) Full text (opens in new tab) Abuse potential hallucinogens Controlled hallucinogens Hallucinogens regulations

TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: A hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?

Neuropharmacology November 2018 Giuseppe Di Giovanni, Philippe De Deurwaerdère

The development of 5-HT2A receptor agonists has been considerably marginalized since the demonstration that the tryptaminergic drugs, LSD and psilocybin, or the phenylakylamine drugs, mescaline and DOI, exert their hallucinogenic properties via the stimulation of 5-HT2A receptors. Nonetheless, the ability of drugs to stimulate 5-HT2A receptors is not necessarily associated with psychedelic...

The entropic brain - revisited.

Neuropharmacology November 1, 2018 Robin Carhart-Harris

The entropic brain hypothesis proposes that within upper and lower limits, after which consciousness may be lost, the entropy of spontaneous brain activity indexes the informational richness of conscious states. Here the hypothesis is revisited four years on from its original publication. It is shown that the principle that the entropy of brain activity is elevated in the psychedelic state is...

Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity.

Neuropharmacology November 2018 Rachael Ingram, Heather Kang, Stafford Lightman et al.

Ketamine, a channel blocking NMDA receptor antagonist, is used off-label for its psychedelic effects, which may arise from a combination of several inter-related actions. Firstly, reductions of the contribution of NMDA receptors to afferent information from external and internal sensory inputs may distort sensations and their processing in higher brain centres. Secondly, reductions of NMDA...

Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.

Neuropharmacology November 2018 David J Heal, Jane Gosden, Sharon L. Smith

Psychedelics comprise drugs come from various pharmacological classes including 5-HT2A agonists, indirect 5-HT agonists, e.g., MDMA, NMDA antagonists and κ-opioid receptor agonists. There is resurgence in developing psychedelics to treat psychiatric disorders with high unmet clinical need. Many, but not all, psychedelics are schedule 1 controlled drugs (CDs), i.e., no approved medical use. For...

Neurological, sensorimotor and cardiorespiratory alterations induced by methoxetamine, ketamine and phencyclidine in mice.

Neuropharmacology October 1, 2018 Andrea Ossato, Sabrine Bilel, Adolfo Gregori et al.

Novel psychoactive substances are intoxicating compounds developed to mimic the effects of well-established drugs of abuse. They are not controlled by the United Nations drug convention and pose serious health concerns worldwide. Among them, the dissociative drug methoxetamine (MXE) is structurally similar to ketamine (KET) and phencyclidine (PCP) and was created to purposely mimic the...

DOI: 10.1016/j.neuropharm.2018.08.017 (opens in new tab) Full text (opens in new tab) Ketamine Behavioral alterations Dissociative drugs Methoxetamine +1

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.

Neuropharmacology September 1, 2018 Dylan Chou, Hsien-Yu Peng, Tzer-Bin Lin et al.

It has been widely reported that ketamine rescues chronic stress-induced depression-like behavior, but the underlying cellular mechanisms of the rapid antidepressant actions of ketamine remain largely unclear. Both male and female Sprague-Dawley rats were used and received modified learned helplessness paradigm to induce depression-like behavior. Depression-like behavior was assayed and...

Temporally dissociable effects of ketamine on neuronal discharge and gamma oscillations in rat thalamo-cortical networks.

Neuropharmacology July 15, 2018 Maria Amat-Foraster, Anders A. Jensen, Niels Plath et al.

Sub-anesthetic doses of the non-competitive N-methyl-d-aspartate receptor (NMDA-R) antagonist ketamine evoke transient psychotomimetic effects, followed by persistent antidepressant effects in treatment-resistant depressed patients and rodents through still poorly understood mechanisms. Since phencyclidine (PCP) disinhibits thalamo-cortical networks by blocking NMDA-Rs on GABAergic neurons of...

DOI: 10.1016/j.neuropharm.2018.04.022 (opens in new tab) Full text (opens in new tab) Ketamine Local field potentials Nmda receptor antagonists Neuronal oscillations +2

Ketamine facilitates extinction of avoidance behavior and enhances synaptic plasticity in a rat model of anxiety vulnerability: Implications for the pathophysiology and treatment of anxiety disorders.

Neuropharmacology July 15, 2018 Ashley M Fortress, Ian M Smith, Kevin C H Pang

Anxiety disorders and posttraumatic stress disorder (PTSD) share a common feature of pathological avoidance behavior. The Wistar Kyoto (WKY) rat has been used as a model of anxiety vulnerability, expressing a behaviorally inhibited temperament, acquiring avoidance behavior more rapidly and displaying extinction-resistant avoidance compared to Sprague Dawley (SD) rats. Subanesthetic levels of...

Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats.

Neuropharmacology July 15, 2018 Daniel G Barrus, Timothy W Lefever, Jenny L Wiley

Edible cannabis-infused products are an increasingly popular method of using cannabis in the United States. Yet, preclinical research to determine mechanisms underlying abuse of Δ9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, has focused primarily on the effects of parenteral administration. The purpose of this study was to examine the rewarding and aversive...

DOI: 10.1016/j.neuropharm.2018.04.018 (opens in new tab) Full text (opens in new tab) Cannabinoid Delta-9-tetrahydrocannabinol Oral Self-administration +1

The psychostimulant (±)-cis-4,4′-dimethylaminorex (4,4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters

Neuropharmacology June 23, 2018 Julian Maier, Felix P. Mayer, Dino Luethi et al. 24 citations

(±)-cis-4,4′-Dimethylaminorex (4,4′-DMAR) is a new psychoactive substance (NPS) that has been associated with 31 fatalities and other adverse events in Europe between June 2013 and February 2014. We used in vitro uptake inhibition and transporter release assays to determine the effects of 4,4′-DMAR on human high-affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin...

DOI: 10.1016/j.neuropharm.2018.06.018 (opens in new tab) Monoamine neurotransmitter Vesicular monoamine transporter Monoaminergic Pharmacology +7

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Neuropharmacology June 5, 2018 Matthew W. Johnson, Roland R. Griffiths, Peter S. Hendricks et al. 348 citations

This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential...

DOI: 10.1016/j.neuropharm.2018.05.012 (opens in new tab) Psilocybin Hallucinogen Substance abuse Pharmacology